Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
US8674081B2 · kind B2 · utility
1Cited by
58References
25Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 8, 2011 |
| Grant date | Mar 18, 2014 |
| Priority date | — |
| Expiry date | Jul 8, 2031 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/70
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a method of treating cancer by providing to a subject in need thereof an immunogenic composition comprising a nucleic acid construct encoding a polypeptide comprising CTL epitopes PSMA288-297 and PRAME425-433, or a cross-reactive analogue. In embodiments of the present invention there is provided methods and compositions for inducing, entraining, and/or amplifying the immune response to MHC class-I restricted epitopes of carcinoma antigens to generate an effective anti-cancer immune response.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.